Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use

被引：0
|
作者：
Gane, E. [1 ]
Seto, W. K. [2 ]
Janssen, H. [3 ]
Caruntu, F. A. [4 ]
Kim, H. J. [5 ]
Abdurakhmanov, D. [6 ]
Nishiguchi, S. [7 ]
Andrzej, H. [8 ]
Bae, H. [9 ]
Mo, S. [10 ]
Suri, V. [10 ]
Gaggar, A. [10 ]
Flaherty, J. F. [10 ]
Kao, J-H [11 ]
Brunetto, M. [12 ]
Buti Ferret, M. [13 ]
机构：
[1] Auckland Clin Studies, Auckland, New Zealand
[2] Queen Mary Hosp, Hong Kong, Peoples R China
[3] Toronto Gen Hosp, Toronto, ON, Canada
[4] Natl Inst Infect Dis Matei Bals, Infect Dis, Bucharest, Romania
[5] Chung Ang Hosp, Seoul, South Korea
[6] Sechenov First Moscow State Med Univ, Moscow, Russia
[7] Hyogo Coll Med Hosp, Nishinomiya, Hyogo, Japan
[8] SP ZOZ Wojewodzki Szpital Zakazny Warszawie, Warsaw, Poland
[9] Asian Pacific Liver Ctr, Los Angeles, CA USA
[10] Gilead Sci Inc, Foster City, CA USA
[11] Natl Taiwan Univ, Taipei, Taiwan
[12] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy
[13] Hosp Univ Vall dHebron, Barcelona, Spain
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：42 / 43
页数：2
相关论文
共 50 条
  • [41] Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
    Wang, Fa-Da
    Zhou, Jing
    Li, Lan-Qing
    Li, Yu-Jing
    Wang, Meng -Lan
    Tao, Ya-Chao
    Zhang, Dong-Mei
    Wang, Yong-Hong
    Chen, En-Qiang
    ANNALS OF HEPATOLOGY, 2023, 28 (05)
  • [42] Safety and efficacy in lamivudine (LAM) experienced chronic hepatitis B (CHB) patients treated for 2 years with tenofovir disoproxil fumarate (TDF)
    Roberts, S. K.
    Gane, E. J.
    Weilert, F.
    Sievert, W.
    George, J.
    Strasser, S. I.
    Kronborg, I.
    Heathcote, E. J.
    Marcellin, P.
    Sorbel, J.
    Rousseau, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A299 - A299
  • [43] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-NEGATIVE, CHRONIC HEPATITIS B PATIENTS: A GLOBAL PHASE 3 STUDY
    Brunetto, Maurizia Rossana
    Lim, Young-Suk
    Gane, Edward
    Seto, Wai-Kay
    Osipenko, Marina
    Ahn, Sang Hoon
    Janssen, Harry L.
    Shukla, Akash
    Chuang, Wan-Long
    Trinh, Huy N.
    Celen, Mustafa
    Flaherty, John F.
    Chan, Alain
    Lau, Audrey
    Gaggar, Anuj
    Suri, Vithika
    Subramanian, Mani
    Pan, Calvin Q.
    Izumi, Namiki
    Marcellin, Patrick
    Chan, Henry L.
    Buti, Maria
    GASTROENTEROLOGY, 2017, 152 (05) : S1086 - S1086
  • [44] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Wang, Chia
    Buti, Maria
    Hadziyannis, Stephanos J.
    Mathurin, Philipe
    Sherman, Morris
    Strasser, Simone I.
    Petersen, Joerg
    Tong, Myron J.
    Sorbel, Jeff
    Mondou, Elsa
    Anderson, Jane
    Rousseau, Franck
    GASTROENTEROLOGY, 2008, 134 (04) : A808 - A809
  • [45] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-POSITIVE PATIENTS: A GLOBAL PHASE 3 STUDY
    Agarwal, Kosh
    Fung, Scott
    Seto, Wai-Kay
    Lim, Young-Suk
    Gane, Edward
    Janssen, Harry L.
    Chuang, Wan-Long
    Bae, Ho
    Yoon, Ki Tae
    Flaherty, John F.
    Lau, Audrey
    Gaggar, Anuj
    Suri, Vithika
    Cathcart, Andrea
    Lin, Lanjia
    Chan, Alain
    Shalimar, Mani Subramanian
    Furusyo, Norihiro
    Buti, Maria
    Chan, Henry L.
    GASTROENTEROLOGY, 2017, 152 (05) : S1085 - S1086
  • [46] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)
    Goorney, B.
    Perez, K.
    HIV MEDICINE, 2019, 20 : 39 - 39
  • [47] Factors associated with regression of cirrhosis in patients with chronic hepatitis B (CHB) infection treated with tenofovir disoproxil fumarate (TDF)
    Gane, Ed
    Afdhal, Nezam
    Buti, Maria
    Elsome, Amanda M.
    Flaherty, John F.
    Martins, Eduardo
    Bekele, Neby
    Bornstein, Jeffrey D.
    Marcellin, Patrick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 164 - 164
  • [48] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Butil, M.
    Hadziyannis, S.
    Mathurin, P.
    Urbanek, P.
    Sherman, M.
    Strasser, S.
    Wang, C.
    Petersen, J.
    Sorbel, J.
    Mondou, E.
    Anderson, J.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S33 - S33
  • [49] Safety of Tenofovir Disoproxil Fumarate (TDF) treatment for the entire pregnancy in mothers with active chronic hepatitis B or cirrhosis
    Pan, Calvin
    Liu, Min
    Cai, Haodong
    Yi, Wei
    HEPATOLOGY, 2013, 58 : 624A - 624A
  • [50] SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2
    Lim, Young-Suk
    Lin, Chun-Yen
    Heo, Jeong
    Bae, Ho
    Chuang, Wan-Long
    Yin, Tak
    Tsang, Owen
    Fournier, Claire
    Hui, Aric Josun
    Trinh, Huy
    Chan, Carol Yee Kwan
    Tan, Susanna K.
    Zhao, Yang
    Flaherty, John F.
    Suri, Vithika
    Gaggar, Anuj
    Brainard, Dianna M.
    Ryder, Stephen
    La Janssen, Harry
    GUT, 2021, 70 : A77 - A77
12345